X-Linked Adrenoleukodystrophy — a treatable progressive brain disease in boys where the window for curative treatment closes as symptoms appear, making genetic diagnosis before neurological onset the difference between cure and disease progression.
Whole genome sequencing identifies ABCD1 pathogenic variants — enabling hematopoietic stem cell transplantation or gene therapy enrollment before the MRI changes that define the narrow treatment window close.
X-Linked Adrenoleukodystrophy
X-linked adrenoleukodystrophy (X-ALD) is an X-linked peroxisomal disorder caused by pathogenic variants in ABCD1 (ATP-binding cassette subfamily D member 1) on chromosome Xq28, encoding the adrenoleukodystrophy protein (ALDP). ALDP transports very-long-chain fatty acids (VLCFA) into peroxisomes for beta-oxidation; its deficiency leads to VLCFA accumulation in the nervous system and adrenal cortex. X-ALD is the most common peroxisomal disorder, affecting approximately 1 in 17,000 males. Carrier females may develop adrenomyeloneuropathy (AMN) — a slowly progressive spinal cord disease — in adulthood, but rarely develop the severe cerebral form.
X-ALD manifests as a spectrum of clinical phenotypes in males. Childhood cerebral ALD (ccALD) — the most feared form — presents between ages 4-10 with behavioral changes, cognitive decline, visual and auditory disturbances, and rapidly progressive neurological deterioration leading to a vegetative state and death within 2-5 years without treatment. Onset is unpredictable; any hemizygous male with ABCD1 pathogenic variant has approximately a 35-40% lifetime risk of developing ccALD, with onset most often in childhood or early adolescence. Adrenomyeloneuropathy (AMN) — in adults — causes slowly progressive spastic paraparesis and peripheral neuropathy. Adrenal insufficiency (Addison disease) occurs in approximately 70-80% of affected males and may be the first manifestation.
The treatment window for cerebral ALD is narrow and MRI-defined: hematopoietic stem cell transplantation (HSCT) and gene therapy (elivaldogene tavalentivec/Lenti-D, approved 2022) halt disease progression but only when MRI lesions are early (Loes score ≤9) and neurological function is preserved. Once significant neurological disability develops, transplantation provides no benefit. This creates intense urgency around early identification — boys with ABCD1 pathogenic variants need brain MRI surveillance every 6 months from ages 4-12, with immediate transplant referral when early MRI changes are detected. X-ALD is now included in newborn screening programs in many U.S. states. Carrier female relatives of affected boys can be identified by ABCD1 testing and counseled about their 35-40% risk of having an affected son.
Genotype-phenotype correlation in X-ALD is poor — the same ABCD1 variant can produce childhood cerebral ALD in one family member and adrenomyeloneuropathy in another. Phenotype cannot be predicted from the genotype, making ongoing surveillance essential for all hemizygous males.
ABCD1 has over 900 documented pathogenic variants with no hotspot — complete gene sequencing is required. Newborn screening plasma VLCFA measurement requires confirmatory ABCD1 sequencing, which whole genome sequencing provides.
Over 900 ABCD1 variants exist with no hotspot — only complete gene sequencing detects them all
Unlike genes with a small number of common recurrent variants, ABCD1 has over 900 distinct pathogenic variants distributed throughout the gene with no single hotspot accounting for more than a few percent of cases. This private variant distribution means that a limited ABCD1 panel would have unacceptably low sensitivity. Newborn screening programs that detect elevated VLCFA on dried blood spot require confirmatory ABCD1 molecular testing to confirm the diagnosis and identify the specific pathogenic variant for family cascade testing. Whole genome sequencing provides complete ABCD1 sequence data, covering all 10 exons and flanking intronic regions, with simultaneous copy number variant analysis.
Cascade testing of at-risk male relatives must happen before the MRI surveillance window opens
When a boy is diagnosed with X-ALD, his mother is an obligate carrier. Her other sons — the patient's brothers — each have a 50% probability of being hemizygous for the ABCD1 variant. If an unidentified brother reaches age 4 without ABCD1 confirmation, he enters the childhood cerebral ALD risk window without the MRI surveillance that would detect early lesions while curative treatment remains possible. Cascade ABCD1 testing of all at-risk male relatives — using the specific familial variant identified by whole genome sequencing — allows all boys to enter the surveillance protocol before the onset window begins, providing the maximum opportunity for curative intervention.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for X-Linked Adrenoleukodystrophy and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
